9 METERS BIOPHARMA, INC.

2022 Q3 Form 10-Q Financial Statement

#000155198622000091 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.86M $29.46M $37.24M
YoY Change -70.41% -53.99% -3.27%
Cash & Equivalents $15.90M $29.46M $37.24M
Short-Term Investments
Other Short-Term Assets $2.593M $1.892M $1.846M
YoY Change -9.67% 7.56% 23.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $18.45M $31.35M $39.09M
YoY Change -67.33% -52.35% -2.24%
LONG-TERM ASSETS
Property, Plant & Equipment $12.95K $14.52K $17.31K
YoY Change -20.93% -1.56% 14.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.580K $5.580K $5.580K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $23.68M $160.4K $176.5K
YoY Change 11672.11% -24.26% -21.17%
TOTAL ASSETS
Total Short-Term Assets $18.45M $31.35M $39.09M
Total Long-Term Assets $23.68M $160.4K $176.5K
Total Assets $42.14M $31.51M $39.26M
YoY Change -25.66% -52.26% -2.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.438M $2.326M $1.912M
YoY Change 9.21% 42.21% 39.48%
Accrued Expenses $6.774M $6.956M $6.256M
YoY Change 14.59% 38.34% 37.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.646M
YoY Change
Total Short-Term Liabilities $12.86M $9.340M $8.224M
YoY Change 76.66% 39.09% 37.37%
LONG-TERM LIABILITIES
Long-Term Debt $15.74M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $67.53K $83.19K $98.39K
YoY Change -47.02% -41.15% -34.41%
Total Long-Term Liabilities $15.74M $83.19K $98.39K
YoY Change 12252.16% -41.15% -34.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.86M $9.340M $8.224M
Total Long-Term Liabilities $15.74M $83.19K $98.39K
Total Liabilities $28.67M $9.423M $8.323M
YoY Change 287.05% 37.43% 35.5%
SHAREHOLDERS EQUITY
Retained Earnings -$200.7M -$191.3M -$180.2M
YoY Change 25.99% 31.27% 31.06%
Common Stock $1.296K $25.91K $25.82K
YoY Change -94.93% 2.72% 19.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.46M $22.09M $30.94M
YoY Change
Total Liabilities & Shareholders Equity $42.14M $31.51M $39.26M
YoY Change -25.66% -52.26% -2.35%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001551986
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37797
dei Entity Registrant Name
EntityRegistrantName
9 METERS BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3948465
dei Entity Address Address Line1
EntityAddressAddressLine1
8480 Honeycutt Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 120
dei Entity Address City Or Town
EntityAddressCityOrTown
Raleigh
dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27615
dei City Area Code
CityAreaCode
919
dei Local Phone Number
LocalPhoneNumber
275-1933
dei Security12b Title
Security12bTitle
Common Stock $0.0001 Par Value
dei Trading Symbol
TradingSymbol
NMTR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
259107380 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29455788 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46993285 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1892310 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2991948 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
31348098 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
49985233 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14522 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16094 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
140278 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
166618 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 usd
CY2022Q2 us-gaap Assets
Assets
31508478 usd
CY2021Q4 us-gaap Assets
Assets
50173525 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2326017 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2434452 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6955632 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5967822 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
58167 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54796 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9339816 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8457070 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
83190 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113142 usd
CY2022Q2 us-gaap Liabilities
Liabilities
9423006 usd
CY2021Q4 us-gaap Liabilities
Liabilities
8570212 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
259107380 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
259107380 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
258235418 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
258235418 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
25911 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
25824 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
213382069 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
210418156 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-191322508 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168840667 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
22085472 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41603313 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31508478 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50173525 usd
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7546477 usd
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5707290 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15914955 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8897592 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3648944 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2551171 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6644715 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4759971 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
11195421 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
8258461 usd
us-gaap Operating Expenses
OperatingExpenses
22559670 usd
us-gaap Operating Expenses
OperatingExpenses
13657563 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11195421 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8258461 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-22559670 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13657563 usd
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
65319 usd
CY2021Q2 us-gaap Interest Income Other
InterestIncomeOther
6505 usd
us-gaap Interest Income Other
InterestIncomeOther
78133 usd
us-gaap Interest Income Other
InterestIncomeOther
11592 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
0 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
1154 usd
us-gaap Interest Expense
InterestExpense
304 usd
us-gaap Interest Expense
InterestExpense
45218 usd
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
65319 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5351 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
77829 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26626 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11130102 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8253110 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22481841 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13684189 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-11130102 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8253110 usd
us-gaap Net Income Loss
NetIncomeLoss
-22481841 usd
us-gaap Net Income Loss
NetIncomeLoss
-13684189 usd
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
259001978 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
259001978 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
249552315 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
249552315 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
258620816 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
258620816 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
230522313 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
230522313 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41603313 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
690000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11351739 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
30941574 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
500000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1774000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-11130102 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
22085472 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32142113 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
422000 usd
CY2021Q1 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
6857028 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75903 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5431079 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
34065965 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34500000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2901123 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
937000 usd
CY2021Q2 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
668439 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
120739 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8253110 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
59137910 usd
us-gaap Net Income Loss
NetIncomeLoss
-22481841 usd
us-gaap Net Income Loss
NetIncomeLoss
-13684189 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2464000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1359000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
43983 usd
us-gaap Depreciation
Depreciation
4414 usd
us-gaap Depreciation
Depreciation
3331 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-7000 usd
nmtr Non Cash Milestone Fees
NonCashMilestoneFees
500000 usd
nmtr Non Cash Milestone Fees
NonCashMilestoneFees
0 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1099638 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
683640 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-108435 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-102373 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
987569 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-262445 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-488 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17534655 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13333821 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2842 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6892 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2842 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6892 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
58199 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
196642 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34500000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2651123 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7525467 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
39512787 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17537497 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
26172074 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46993285 usd
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37851388 usd
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
258235418 shares
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29455788 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64023462 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
569 usd
nmtr Noncash Addition Of Stock Offering Costs
NoncashAdditionOfStockOfferingCosts
0 usd
nmtr Noncash Addition Of Stock Offering Costs
NoncashAdditionOfStockOfferingCosts
250000 usd
CY2020Q4 nmtr Sale Of Stock Shelf Registration Maximum Equity Offering Price
SaleOfStockShelfRegistrationMaximumEquityOfferingPrice
200000000 usd
CY2022Q2 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
5439111 usd
CY2021Q4 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4228048 usd
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation allowance for income tax assets, and management’s assessment of the Company’s ability to continue as a going concern. The Company considered the impact of the COVID-19 pandemic on its estimates and assumptions, and concluded there was not a material impact to its condensed consolidated financial statements as of and for the three and six months ended June 30, 2022. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</span></div>
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1421272 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1633295 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
95249 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106479 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6955632 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5967822 usd
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
63507506 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
52200000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
52200000 shares
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47200000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47200000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
52220051 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47193016 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29500000 usd
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q2 nmtr Number Of Amended And Restated License Agreements
NumberOfAmendedAndRestatedLicenseAgreements
2 licenseagreement
CY2021Q3 nmtr Milestone Payment
MilestonePayment
500000 usd
CY2022Q2 nmtr Accrued Milestone Fees
AccruedMilestoneFees
500000 usd
nmtr Accrued Milestone Fees
AccruedMilestoneFees
500000 usd
nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 usd
CY2021Q2 nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 usd
CY2021Q2 nmtr Capital Stock Shares Authorized
CapitalStockSharesAuthorized
560000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
259107380 shares
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
49417616 shares
CY2022Q2 nmtr Number Of Stock Option Plans
NumberOfStockOptionPlans
3 equity-basedincentiveplan
nmtr Share Based Compensation Arrangement By Share Based Payment Award Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedTerm
P10Y
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1774000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
937000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2464000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1359000 usd
nmtr Severance Provisions Annual Base Salary Period
SeveranceProvisionsAnnualBaseSalaryPeriod
P12M
nmtr Severance Provisions Continuation Of Health Insurance Benefits Period
SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod
P12M
nmtr Severance Provisions Termination Or Resignation Annual Base Salary Period
SeveranceProvisionsTerminationOrResignationAnnualBaseSalaryPeriod
P18M
CY2021Q2 us-gaap Severance Costs1
SeveranceCosts1
0 usd
CY2022Q2 us-gaap Severance Costs1
SeveranceCosts1
0 usd
us-gaap Severance Costs1
SeveranceCosts1
0 usd
us-gaap Severance Costs1
SeveranceCosts1
0 usd
CY2022Q2 nmtr Deferred Compensation Liability Severance Accrual
DeferredCompensationLiabilitySeveranceAccrual
200000 usd
CY2021Q4 nmtr Deferred Compensation Liability Severance Accrual
DeferredCompensationLiabilitySeveranceAccrual
400000 usd
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 nmtr Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
72000 usd
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 usd
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 usd
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233206 usd
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
233206 usd
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
36000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
36000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
100000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
36000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
72000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
54000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
162000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
20643 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
141357 usd

Files In Submission

Name View Source Status
0001551986-22-000091-index-headers.html Edgar Link pending
0001551986-22-000091-index.html Edgar Link pending
0001551986-22-000091.txt Edgar Link pending
0001551986-22-000091-xbrl.zip Edgar Link pending
ex-101ebrislicenseagreement.htm Edgar Link pending
ex311q22022.htm Edgar Link pending
ex312q22022.htm Edgar Link pending
ex321q22022.htm Edgar Link pending
ex322q22022.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nmtr-20220630.htm Edgar Link pending
nmtr-20220630.xsd Edgar Link pending
nmtr-20220630_g1.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nmtr-20220630_cal.xml Edgar Link unprocessable
nmtr-20220630_def.xml Edgar Link unprocessable
nmtr-20220630_pre.xml Edgar Link unprocessable
nmtr-20220630_lab.xml Edgar Link unprocessable
nmtr-20220630_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending